ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients.

Details

Serval ID
serval:BIB_6CC4A69B8A68
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients.
Journal
Journal of Antimicrobial Chemotherapy
Author(s)
Maertens J., Cesaro S., Maschmeyer G., Einsele H., Donnelly J.P., Alanio A., Hauser P.M., Lagrou K., Melchers W.J., Helweg-Larsen J., Matos O., Bretagne S., Cordonnier C., 5th European Conference on Infections in Leukaemia (ECIL-5)  a joint venture of the European Group for Blood, Marrow Transplantation (EBMT)  the European Organisation for Research, Treatment of Cancer (EORTC)  the Immunocompromised Host Society (ICHS)
Working group(s)
the European LeukemiaNet (ELN)
Contributor(s)
Agrawal S., Akova M., Alanio A., Aljurf M., Averbuch D., Berg T., Blennow O., Bretagne S., Brüggemann R., Calandra T., Castagnola E., Cesaro S., Cordonnier C., Cornely O., De La Camara R., Donnelly P., Drgona L., Duarte R., Einsele H., Engelhard D., Girmenia C., Hargreaves R., Hauser P., Helweg-Larsen J., Herbrecht R., Hirsch H., Hubacek P., Kibbler C., Klyasova G., Kouba M., Kullberg BJ., Lagrou K., Ljungman P., Maertens J., Mallet V., Marchetti O., Maschmeyer G., Matos O., Melchers W., Mikulska M., Munoz P., Orasch C., Pagano L., Pagliuca A., Penack O., Pettrikos G., Racil Z., Ribaud P., Rizzi-Puechal V., Roilides E., Sinko J., Skiada A., Slavin M., Styczynski J., Tissot F., Tweddle L., van Boemmel F., von Lilienfeld-Toal M., Viscoli C., Ward K., Wood C.
ISSN
1460-2091 (Electronic)
ISSN-L
0305-7453
Publication state
Published
Issued date
2016
Peer-reviewed
Oui
Volume
71
Number
9
Pages
2397-2404
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Abstract
The 5th European Conference on Infections in Leukaemia (ECIL-5) meeting aimed to establish evidence-based recommendations for the prophylaxis of Pneumocystis jirovecii pneumonia (PCP) in non-HIV-infected patients with an underlying haematological condition, including allogeneic HSCT recipients. Recommendations were based on the grading system of the IDSA. Trimethoprim/sulfamethoxazole given 2-3 times weekly is the drug of choice for the primary prophylaxis of PCP in adults ( A-II: ) and children ( A-I: ) and should be given during the entire period at risk. Recent data indicate that children may benefit equally from a once-weekly regimen ( B-II: ). All other drugs, including pentamidine, atovaquone and dapsone, are considered second-line alternatives when trimethoprim/sulfamethoxazole is poorly tolerated or contraindicated. The main indications of PCP prophylaxis are ALL, allogeneic HSCT, treatment with alemtuzumab, fludarabine/cyclophosphamide/rituximab combinations, >4 weeks of treatment with corticosteroids and well-defined primary immune deficiencies in children. Additional indications are proposed depending on the treatment regimen.
Pubmed
Web of science
Open Access
Yes
Create date
16/09/2016 14:51
Last modification date
20/08/2019 14:26
Usage data